Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 9/20 | 0.40 |
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.38 |
| ▸ | NAA50 | Q9GZZ1 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.38 |
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
| ▸ | REN | P00797 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28890650 | 0.94 | APLNR (0.40) | APLNRF2NAA50NTMT1FAP | |
| SCHEMBL31544467 | 0.94 | APLNR (0.40) | APLNRF2NAA50NTMT1FAP | |
| SCHEMBL4726312 | 0.94 | APLNR (0.40) | APLNRF2NAA50NTMT1FAP | |
| SCHEMBL4726314 | 0.94 | APLNR (0.40) | APLNRF2NAA50NTMT1FAP | |
| SCHEMBL31070022 | 0.93 | APLNR (0.42) | APLNRF2NAA50NTMT1FAP | |
| SCHEMBL4258292 | 0.92 | F2 (0.39) | ACEAPLNRF2NAA50NTMT1 | |
| SCHEMBL30353946 | 0.91 | ACE (0.41) | ACEAPLNRNAA50ACE2FAP | |
| SCHEMBL29832781 | 0.91 | APLNR (0.38) | APLNRF2NAA50NTMT1FAP | |
| SCHEMBL29411115 | 0.88 | ACE (0.49) | ACEAPLNRF2NTMT1 | |
| SCHEMBL30563229 | 0.87 | ACE (0.45) | ACEF2ACE2REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120004984-A | Cyclic lactam compound and liquid phase synthesis method thereof | 上海瑗肽生化科技有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-120004974-A | Liquid phase synthesis method of cyclic lactam compound | 上海瑗肽生化科技有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-117384991-A | Preparation method and application of high-bioactivity cyclic peptide | 上海中翊日化有限公司 | 2024-01-12 | — | — | CN | disclosed |
| US-20080075798-A1 | Personal care compositions comprising pear seed extract | PROCTER & GAMBLE COMPANY, THE | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080075798-A1 | Personal care compositions comprising pear seed extract | CUTA, POLR1C, DPM1 | ACE 2173/4885APLNR 1269/4885F2 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.